The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Understand the basic biology behind cystic fibrosis and the approaches to treat the underlying cause of the disease – mutations in the CF transmembrane regulator (CFTR) gene. Learn how mutations in different parts of the gene result in diverse protein defects, and in some cases complete loss of CFTR protein. This session will also break down the most common approaches for genetic therapies, which aim to restore functional CFTR expression by delivering RNA, DNA, or DNA editing machinery. If successful, these therapies could benefit all people with CF, including those with rare or nonsense mutations. To close the session, you will hear about the challenge of packaging and delivering genetic therapies for CF and learn how the Foundation is working to overcome this hurdle.
Speaker(s):
Kara
Foshay,
PhD,
Director of Biopharma and Medicine Programs,
Cystic Fibrosis Foundation
John
Sheridan,
PhD,
Ongoing Research Director,
Cystic Fibrosis Foundation
You must be logged in and own this session in order to
post comments.
